drugset / Trial / NCT06549959

A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects

NCT06549959

Phase 1 Recruiting 248 enrolled RemeGen Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, randomized, parallel group, single dose study in healthy Chinese subjects. The purpose of this study is to evaluate the Pharmacokinetics and safety of Telitacicept Pre-filled Injection and Freeze-dried powder Injection.

Timeline

Start
2024-08-05
Primary completion
2024-11-30
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Telitacicept Protein / enzyme biologic 80 mg

Indications

No indication recorded.